Next-gen protein assays enabling precision medicine and data-driven biology

C.E. Credits: Florida CE P.A.C.E. CE
Speaker

Abstract

Proteins are the functional blocks of any biological entity from 50 nm sized viruses to the 100 ft long mammals (blue whale). They perform intra cellular, tissue, organ, system, or organism level essential functions. As one of the most diverse, the human proteome consists of millions of different proteins serving even a greater number of functions. Most diseases are viewed and targeted from a proteomic perspective via 1) a result of functional change of a protein, 2) up or down regulation of a protein 3) or introduction of intruder proteins to serve intruder functions (ie infection). In this perspective, most drugs developed in pharma (along with the ones in the pipeline) are either a small molecule targeting a protein, or they are proteins themselves, or involves a genomic approach again targeting to fix a proteomic problem at the functional level. While in the early stage discovery phase, mass spec is utilized; in most downstream stages of R&D, immunoassays are the work horse. Every day, the relevance of proteomic data for actionable outcomes is increasing.  Despite this interest, from the early days since the technology was introduced (1950s), immunoassays have not seen much of a change.  The principle underlying biophysics still relies on diffusion limited interaction of a capture molecule (usually an antibody) and the target molecule. Expanding on the above discussion, we will talk about the biophysical challenges prohibiting the ubiquitous adoption of immunoassays and general shortcomings. Later we will discuss how Correlia’s ANDI gel technology coupled with advanced automation offers complete workflow solutions, speeds up assays, and reduces sample use.  We will also discuss how these value offerings increase decision making prover, open up new possibilities in precision medicine, and enable more data driven biology. The talk will end with reflections over the role of efficient immunoassays in the fight with COVID-19.

Learning Objectives:

1. How microfluidics advancements coupled with automation offer solutions to overcome challenges with 70-year-old ELISA technology

2. How above solutions can be applied to precision medicine, pharma drug development, and the fight with COVID-19


Show Resources
You May Also Like
MAY 11, 2021 10:00 AM PDT
C.E. CREDITS
MAY 11, 2021 10:00 AM PDT
Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
OCT 20, 2021 10:00 AM PDT
C.E. CREDITS
OCT 20, 2021 10:00 AM PDT
Date: October 20, 2021 Time:10:00am (PDT), 1:00pm (EDT) As the prevalence of Diabetes continues to rise in many areas across the globe, healthcare providers continue to look for methods that...
OCT 12, 2021 9:00 AM PDT
C.E. CREDITS
OCT 12, 2021 9:00 AM PDT
Date: October 12, 2021 Time: 9:00am (PDT), 12:00pm (EDT) SCIEX’s next-generation Biologics Explorer software is an innovative platform for the comprehensive and deep characterization o...
JUN 09, 2021 7:00 AM PDT
C.E. CREDITS
JUN 09, 2021 7:00 AM PDT
Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
SEP 17, 2021 12:00 PM CST
C.E. CREDITS
SEP 17, 2021 12:00 PM CST
Date: September 16, 2021 Time: 9:00pm (PDT), 12:00am (EDT) 3D cellular models like organoids and spheroids offer an opportunity to better understand complex biology in a physiologically rele...
Loading Comments...
Show Resources